Use abm’s All-in-One lentivectors and lentiviruses that express spCas9 or FnCas12a (FnCpf1) along with the sgRNA to simplify the delivery of CRISPR/Cas9 technology right into the target cell. Alternatively, custom sgRNA lentivectors and lentiviruses can be used to deliver sgRNAs into cells that already express the spCas9 nuclease, and thus recruit spCas9 to the target gene (Check out abm’s Cas9-Expressing Stable Cell Lines).
Lentiviruses can infect both dividing and non-dividing cells in vitro and in vivo, and will integrate stably into the host cell genome, ensuring long-term expression of the construct even in cells that are difficult to infect. Lentivectors, on the other hand, allow transient expression and can be diluted out.
"I have used abm's All-in-One lentiviral system to knockout human IL11, which worked really well. Our labmate also ordered the same system from abm to knockout mouse Axl, and she got good results, too. Thus, we want to stick to the same system."
Dr. Ejung Moon, Stanford University, CRISPR
Service Details
Cloning Services
Service Name
Vector
Quantity
Cat. No.
Price
Custom CRISPR sgRNA Lentiviral Vector (for spCas9) – single target
We do the titration after aliquoting and freeze-down. Thus, the titer should be accurate for the customer after they thaw the finished product for the first time.
Our lentivirus expression system is derived from Human HIV-1 Virus. It employs third generation self-inactivating recombinant lentiviral vectors with enhanced biosafety features and minimal relation to wild-type Human HIV-1 Virus.
Kang, Y. J. et al. "Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling." Nat. Commun. (2015) 6:8371 doi: 10.1038/ncomms9371
Jiang, G. et al. "Isorhapontigenin (ISO) inhibits invasive bladder cancer (BC) formation in vivo and human BC invasion in vitro by targeting STAT1/FOXO1 Axis." Cancer Prev Res. Published Online First April 14, 2016.doi: 10.1158/1940-6207.CAPR-15-0338
Okugawa, Y. et al. "Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer." Gut (2015)doi:10.1136/gutjnl-2015-309359